Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.71 |
| ▸ | DRD3 | P35462 | 4/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | DRD1 | P21728 | 3/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.71 |
| ▸ | BCL2 | P10415 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6475987 | 0.97 | CYP2D6 (0.70) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL3977325 | 0.90 | OPRM1 (0.66) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL7668121 | 0.88 | CHRM2 (0.83) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL16769329 | 0.87 | KCNH2 (0.76) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL13900811 | 0.87 | KCNH2 (0.76) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL7283040 | 0.86 | KCNH2 (0.66) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Water SCHEMBL7268832 | 0.85 | KCNH2 (0.64) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL27598786 | 0.84 | CHRM2 (0.67) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL27705907 | 0.84 | CHRM2 (0.67) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL27686841 | 0.84 | CHRM2 (0.67) | KCNH2CHRM2ADRA2ADRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030205-A1 | Process for obtaining cetirizine dihydrochloride | COSMA S.P.A. | 2009-01-29 | — | — | US | claimed |
| EP-2019096-A1 | Process for obtaining Cetirizine dihydrochloride | Cosma S.p.A. (IT) | 2009-01-28 | — | — | EP | claimed |
| EP-1233954-B1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-10-20 | — | — | EP | claimed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | claimed |
| US-20090030205-A1 | Process for obtaining cetirizine dihydrochloride | COSMA S.P.A. | 2009-01-29 | — | — | US | disclosed |
| US-20090030205-A1 | Process for obtaining cetirizine dihydrochloride | COSMA S.P.A. | 2009-01-29 | — | — | US | disclosed |
| EP-2019096-A1 | Process for obtaining Cetirizine dihydrochloride | Cosma S.p.A. (IT) | 2009-01-28 | — | — | EP | disclosed |
| EP-2019096-A1 | Process for obtaining Cetirizine dihydrochloride | Cosma S.p.A. (IT) | 2009-01-28 | — | — | EP | disclosed |
| US-6908999-B2 | Hydrolysis of N,N-disubstituted (2-(4-(alpha-phenyl-p-chloro-benzyl)piperazin-1-yl)ethoxy)acetamide, to form cetirizine and salts, used as antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2005-06-21 | — | — | US | disclosed |
| EP-1233954-B1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-10-20 | — | — | EP | disclosed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | disclosed |
| EP-1233954-A1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040211-A1 | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | CMA1, NAT1, CPN1 | KCNH2 2290/4885CHRM2 297/4885ADRA2A 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.